Pattern Anlysis of Risk-Reducing Strategies in Unaffected Korean BRCA1/2 Mutation Carriers

被引:0
作者
Kim, Dabin [1 ]
Ryu, Jai Min [2 ]
Han, Sang-Ah [3 ]
Kim, Zisun [1 ]
Kim, Sung-Won [4 ]
机构
[1] Soonchunhyang Univ, Bucheon Hosp, Dept Surg, Coll Med, Bucheon 14584, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Breast Surg,Dept Surg, Seoul 06351, South Korea
[3] Kyung Hee Univ Hosp Gangdong, Dept Surg, Seoul 05278, South Korea
[4] Daerim St Marys Hosp, Dept Surg, Seoul 07442, South Korea
关键词
hereditary breast and ovarian cancer syndrome; BRCA1; gene; BRCA2; prophylactic mastectomy; HEREDITARY BREAST-CANCER; SALPINGO-OOPHORECTOMY; PROPHYLACTIC MASTECTOMY; OVARIAN-CANCER; WOMEN; MAMMOGRAPHY; SURGERY;
D O I
10.3390/curroncol31110499
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The lifetime risk of breast and ovarian cancer increases substantially for individuals with mutations in BRCA1/2. The evidence indicates that BRCA1/2 mutation carriers benefit from early cancer detection and prevention strategies. However, data on the patterns of risk-reducing interventions are lacking. This study investigated the patterns of surveillance and risk-reducing interventions among unaffected BRCA1/2 mutation carriers. A cohort of unaffected BRCA1/2 mutation carriers was identified from the Korean Hereditary Breast cAncer (KOHBRA) study database, and a telephone survey was conducted. The survey included questions on the incidence of new cancers, patterns of cancer (breast, ovarian, prostate, other) surveillance, chemoprevention, risk-reducing surgery, and reasons for participating in risk-reducing strategies. Between November 2016 and November 2020, 192 BRCA1/2 mutation carriers were contacted, of which 83 responded. After excluding 37 responders who refused to participate, 46 participants (15 males, 31 females) were included in the analysis. The mean +/- SD follow-up time was 103 +/- 17 months (median 107, range 68 similar to 154), and the mean +/- SD age was 31 +/- 8 years. Ten BRCA1/2 mutation carriers developed breast cancer, one developed ovarian cancer, and three developed other cancers. Six BRCA1/2 mutation carriers (19.4%) underwent annual breast cancer surveillance as recommended by guidelines, while none underwent ovarian or prostate cancer surveillance. Three carriers (9.7%) used chemoprevention for breast cancer. Risk-reducing salpingo-oophorectomy was performed on only one BRCA1/2 mutation carrier. The rates of breast/ovarian cancer surveillance, chemoprevention, and risk-reducing surgery were low among unaffected Korean BRCA1/2 mutation carriers. Given this cohort's relatively high risk of developing breast cancer, strategies to encourage active participation in risk reduction are needed.
引用
收藏
页码:6767 / 6777
页数:11
相关论文
共 32 条
[1]  
[Anonymous], 2019, NCCN CLIN PRACTICE G
[2]  
Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
[3]   Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer [J].
Castro, Elena ;
Goh, Chee ;
Olmos, David ;
Saunders, Ed ;
Leongamornlert, Daniel ;
Tymrakiewicz, Malgorzata ;
Mahmud, Nadiya ;
Dadaev, Tokhir ;
Govindasami, Koveela ;
Guy, Michelle ;
Sawyer, Emma ;
Wilkinson, Rosemary ;
Ardern-Jones, Audrey ;
Ellis, Steve ;
Frost, Debra ;
Peock, Susan ;
Evans, D. Gareth ;
Tischkowitz, Marc ;
Cole, Trevor ;
Davidson, Rosemarie ;
Eccles, Diana ;
Brewer, Carole ;
Douglas, Fiona ;
Porteous, Mary E. ;
Donaldson, Alan ;
Dorkins, Huw ;
Izatt, Louise ;
Cook, Jackie ;
Hodgson, Shirley ;
Kennedy, M. John ;
Side, Lucy E. ;
Eason, Jacqueline ;
Murray, Alex ;
Antoniou, Antonis C. ;
Easton, Douglas F. ;
Kote-Jarai, Zsofia ;
Eeles, Rosalind .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) :1748-+
[4]   BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients A Review [J].
Cheng, Heather H. ;
Shevach, Jeffrey W. ;
Castro, Elena ;
Couch, Fergus J. ;
Domchek, Susan M. ;
Eeles, Rosalind A. ;
Giri, Veda N. ;
Hall, Michael J. ;
King, Mary-Claire ;
Lin, Daniel W. ;
Loeb, Stacy ;
Morgan, Todd M. ;
Offit, Kenneth ;
Pritchard, Colin C. ;
Schaeffer, Edward M. ;
Szymaniak, Brittany M. ;
Vassy, Jason L. ;
Katona, Bryson W. ;
Maxwell, Kara N. .
JAMA ONCOLOGY, 2024, 10 (09) :1272-1281
[5]   The role of BRCA2 in replication-coupled DNA interstrand cross-link repair in vitro [J].
Cipak, Lubos ;
Watanabe, Norifumi ;
Bessho, Tadayoshi .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2006, 13 (08) :729-733
[6]   Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers [J].
Disilvestro, Jessica B. ;
Haddad, Jessica ;
Robison, Katina ;
Beffa, Lindsey ;
Laprise, Jessica ;
Scalia-Wilbur, Jennifer ;
Raker, Christina ;
Clark, Melissa A. ;
Lokich, Elizabeth ;
Hofstatter, Erin ;
Dalela, Disha ;
Brown, Amy ;
Bradford, Leslie ;
Toland, Maris ;
Stuckey, Ashley .
JOURNAL OF WOMENS HEALTH, 2024, 33 (05) :624-628
[7]   Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers:: a prospective cohort study [J].
Domchek, SM ;
Friebel, TM ;
Neuhausen, SL ;
Wagner, T ;
Evans, G ;
Isaacs, C ;
Garber, JE ;
Daly, M ;
Eeles, R ;
Matloff, E ;
Tomlinson, GE ;
Van't Veer, L ;
Lynch, HT ;
Olopade, O ;
Weber, BL ;
Rebbeck, TR .
LANCET ONCOLOGY, 2006, 7 (03) :223-229
[8]   Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality [J].
Domchek, Susan M. ;
Friebel, Tara M. ;
Singer, Christian F. ;
Evans, D. Gareth ;
Lynch, Henry T. ;
Isaacs, Claudine ;
Garber, Judy E. ;
Neuhausen, Susan L. ;
Matloff, Ellen ;
Eeles, Rosalind ;
Pichert, Gabriella ;
Van T'veer, Laura ;
Tung, Nadine ;
Weitzel, Jeffrey N. ;
Couch, Fergus J. ;
Rubinstein, Wendy S. ;
Ganz, Patricia A. ;
Daly, Mary B. ;
Olopade, Olufunmilayo I. ;
Tomlinson, Gail ;
Schildkraut, Joellen ;
Blum, Joanne L. ;
Rebbeck, Timothy R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (09) :967-975
[9]   Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations -: Facts and controversy [J].
Eisen, A ;
Weber, BL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :207-208
[10]  
Friedenson Bernard, 2005, MedGenMed, V7, P60